Article
Continuation of epidermal growth factor receptor tyrosine kinase inhibitor treatment prolongs disease control in non-small-cell lung cancers with acquired resistance to EGFR tyrosine kinase inhibitors.
Oncotarget - 22 Sept 2015
Chen Qi, Quan Qi, Ding Lingyu, Hong Xiangchan, Zhou Ningning, Liang Ying, Wu Haiying
Abstract excerpt
OBJECTIVES: Patients with non-small-cell lung cancer (NSCLC) develop acquired resistance to epidermal growth factor receptor tyrosine kinase inhibitors (EGFR TKIs) after tumor regression. No approved targeted therapies are currently available after initial EGFR TKI treatment. This study investigated the efficacy of continuing EGFR TKI therapy with local treatments for patients with NSCLC and local progression or...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.